Glaukos (FRA:6GJ) E10: €-1.42 (As of Mar. 2026)


FRA:6GJ Glaukos Corp FRA:6GJ
78 GF Score
Price €123.00
GF Value €119.51
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Glaukos E10?

Glaukos FRA:6GJ -2.38% 78 E10 is €-1.42 as of Mar. 2026. GuruFocus rates FRA:6GJ with a GF Score™ of 78/100 and a GF Value™ of €119.51 (Fairly Valued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Glaukos's adjusted earnings per share data for the three months ended in Mar. 2026 was €-0.294. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-1.42 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-07-01), Glaukos's current stock price is €123.00. Glaukos's E10 for the quarter that ended in Mar. 2026 was €-1.42. Glaukos's Shiller PE Ratio of today is .


Glaukos  (FRA:6GJ) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Glaukos E10 Related Terms


Glaukos E10 Historical Data

* Premium members only.

The historical data trend for Glaukos's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Glaukos E10 Chart

Glaukos Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -2.19 -2.59 -1.38

Glaukos Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.62 -1.13 -1.17 -1.38 -1.42

FRA:6GJ vs BIO, BRKR, PODD: E10 Comparison

For the Medical Devices subindustry, Glaukos's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Glaukos Shiller PE Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Glaukos's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Glaukos's Shiller PE Ratio falls into.


FRA:6GJ
78GF Score
Glaukos Corp FRA:6GJ
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Glaukos E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Glaukos's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.294/330.2130*330.2130
=-0.294

Current CPI (Mar. 2026) = 330.2130.

Glaukos Quarterly Data

per share eps CPI Adj_EPS
201606 0.053 241.018 0.073
201609 0.027 241.428 0.037
201612 0.003 241.432 0.004
201703 0.019 243.801 0.026
201706 -0.089 244.955 -0.120
201709 0.034 246.819 0.045
201712 0.025 246.524 0.033
201803 -0.065 249.554 -0.086
201806 -0.128 251.989 -0.168
201809 -0.163 252.439 -0.213
201812 0.035 251.233 0.046
201903 -0.035 254.202 -0.045
201906 -0.150 256.143 -0.193
201909 -0.336 256.759 -0.432
201912 0.756 256.974 0.971
202003 -1.122 258.115 -1.435
202006 -0.799 257.797 -1.023
202009 -0.297 260.280 -0.377
202012 -0.197 260.474 -0.250
202103 -0.302 264.877 -0.376
202106 -0.315 271.696 -0.383
202109 0.111 274.310 0.134
202112 -0.416 278.802 -0.493
202203 0.100 287.504 0.115
202206 -0.908 296.311 -1.012
202209 -0.586 296.808 -0.652
202212 -0.623 296.797 -0.693
202303 -0.672 301.836 -0.735
202306 -0.628 305.109 -0.680
202309 -0.590 307.789 -0.633
202312 -0.688 306.746 -0.741
202403 -0.754 312.332 -0.797
202406 -0.929 314.175 -0.976
202409 -0.351 315.301 -0.368
202412 -0.573 315.605 -0.600
202503 -0.296 319.799 -0.306
202506 -0.295 322.561 -0.302
202509 -0.239 324.800 -0.243
202512 -1.981 324.054 -2.019
202603 -0.294 330.213 -0.294

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-1.42 mean?
Glaukos (FRA:6GJ) has a E10 of €-1.42 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Glaukos and its competitors.
Is Glaukos' E10 too high?
Glaukos' current E10 is €-1.42. Overall, Glaukos has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Glaukos' E10 compare to BIO and BRKR?
Glaukos' E10 of €-1.42 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Medical Devices & Instruments company?
A good E10 depends on the Medical Devices & Instruments industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Glaukos and its competitors. Glaukos's current E10 is €-1.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glaukos stock overvalued right now?
Based on GuruFocus' analysis, Glaukos (FRA:6GJ) is currently considered Fairly Valued. The stock's GF Value™ is €119.51, compared to a current price of €123.00 — trading 2.9% above its estimated fair value. The current E10 is €-1.42. Glaukos' overall GF Score™ is 78/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Glaukos (FRA:6GJ), the current E10 is €-1.42 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Glaukos (FRA:6GJ) Overvalued in 2026?

Based on GuruFocus' analysis, Glaukos stock appears to be overvalued. The current stock price of €123.00 is trading 2.9% above its estimated GF Value™ of €119.51. GuruFocus considers Glaukos to be Fairly Valued.

Key valuation signals for FRA:6GJ:

  • E10: €-1.42
  • GF Value™: €119.51 vs. price of €123.00 (2.9% above fair value)
  • GF Score™: 78/100 with 6 warning signs

No single metric tells the full story. See the FRA:6GJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Glaukos Business Description

Other Exchanges GKOS:USA
Address One Glaukos Way, Aliso Viejo, CA, USA, 92656
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
78GF Score

Get the complete analysis for FRA:6GJ

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€123.00
Price
€119.51
GF Value